Chembio Diagnostics Profit Margin 2006-2018 | CEMI

Current and historical gross margin, operating margin and net profit margin for Chembio Diagnostics (CEMI) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Chembio Diagnostics net profit margin as of December 31, 2018 is -23.54%.
Chembio Diagnostics Annual Profit Margins
Chembio Diagnostics Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.097B $0.033B
CHEMBIO DIAGNOSTICS, INC. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $5 billion point-of-care testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by a third party company. Chembio markets its HIV STAT-PAK line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors. Chembio also has rapid tests for veterinary tuberculosis and chagas disease. In 2007 Chembio received a U.S. patent for its Dual Path Platform technology which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products based on DPP. Chembio is licensed by the U.S. Food and Drug Administration as well as the U. S. Department of Agriculture, and is certified for the global market under the International Standards Organization directive 13.485.
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $140.623B 27.80
Medtronic (MDT) Ireland $123.520B 18.06
Stryker (SYK) United States $73.875B 27.09
Boston Scientific (BSX) United States $52.874B 25.78
Baxter (BAX) United States $40.209B 25.72
Zimmer Biomet Holdings (ZBH) United States $26.486B 16.96
Smith & Nephew SNATS (SNN) United Kingdom $17.634B 0.00
Canopy Growth (CGC) Canada $15.407B 0.00
ResMed (RMD) United States $14.469B 27.44
Aurora Cannabis (ACB) Canada $9.687B 68.36
Bio-Rad Laboratories (BIO) United States $9.455B 53.94
Hill-Rom Holdings (HRC) United States $7.140B 22.08
Perrigo (PRGO) Ireland $6.601B 10.70
Insulet (PODD) United States $6.039B 2037.40
GW Pharmaceuticals (GWPH) United Kingdom $5.309B 0.00
ICU Medical (ICUI) United States $4.841B 30.14
Haemonetics (HAE) United States $4.496B 39.88
Hutchison China MediTech (HCM) China $3.961B 0.00
Agios Pharmaceuticals (AGIO) United States $3.830B 0.00
Neogen (NEOG) United States $3.332B 51.18
NuVasive (NUVA) United States $2.927B 25.53
Quidel (QDEL) United States $2.672B 24.11
Aphria (APHA) $2.518B 111.78
National Vision Holdings (EYE) United States $2.327B 45.77
HEXO (HEXO) $1.429B 0.00
Cardiovascular Systems (CSII) United States $1.402B 1006.25
Phibro Animal Health (PAHC) United States $1.308B 18.80
VAREX IMAGING (VREX) United States $1.299B 25.44
AtriCure (ATRC) United States $1.104B 0.00
Lantheus Holdings (LNTH) United States $0.968B 26.15
MacroGenics (MGNX) United States $0.967B 0.00
Cerus (CERS) United States $0.885B 0.00
PetIQ (PETQ) United States $0.872B 24.96
Omeros (OMER) United States $0.868B 0.00
NanoString Technologies (NSTG) United States $0.753B 0.00
Meridian Bioscience (VIVO) United States $0.727B 21.67
OraSure Technologies (OSUR) United States $0.713B 31.24
Eagle Pharmaceuticals (EGRX) United States $0.705B 23.99
Evolus (EOLS) United States $0.701B 0.00
TG Therapeutics (TGTX) United States $0.650B 0.00
Surmodics (SRDX) United States $0.618B 89.94
LeMaitre Vascular (LMAT) United States $0.614B 29.21
Quanterix (QTRX) United States $0.551B 0.00
BioLife Solutions (BLFS) United States $0.397B 163.54
Vapotherm (VAPO) United States $0.371B 0.00
Rockwell Medical (RMTI) United States $0.363B 0.00
Insys Therapeutics (INSY) United States $0.358B 0.00
Utah Medical Products (UTMD) United States $0.312B 20.30
Owens & Minor (OMI) United States $0.284B 3.94
Bovie Medical (APYX) United States $0.264B 0.00
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.257B 0.00
Cytosorbents (CTSO) United States $0.255B 0.00
Zynex (ZYXI) United States $0.143B 15.35
Fonar (FONR) United States $0.143B 7.64
Surface Oncology (SURF) United States $0.117B 0.00
Chimerix (CMRX) United States $0.102B 0.00
Female Health (VERU) United States $0.100B 0.00
InfuSystems Holdings (INFU) United States $0.090B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.088B 0.00
United-Guardian (UG) United States $0.087B 20.01
CAS Medical Systems (CASM) United States $0.071B 0.00
Trinity Biotech (TRIB) Ireland $0.071B 21.00
Neurotrope (NTRP) United States $0.061B 0.00
Oramed Pharmaceuticals (ORMP) United States $0.056B 0.00
ImmuCell (ICCC) United States $0.038B 0.00
Valeritas Holdings (VLRX) United States $0.036B 0.00
Senestech (SNES) United States $0.028B 0.00
Myomo (MYO) United States $0.022B 0.00
Capricor Therapeutics (CAPR) United States $0.018B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.015B 0.00
Akers Biosciences Inc (AKER) United States $0.014B 0.00
Cellectar Biosciences (CLRB) United States $0.012B 0.00
NeuroMetrix (NURO) United States $0.009B 15.57